THERANOSTICS 2016* , ,
Presentations this author is a contributor to:
Requirements on Specific Activity (SA) of 177Lu to Radiolabel DOTA-peptides for PRRT. Studies on Labeling a Typical Formulation of 0.1 mg DOTA-PSMA-617 (=0.1 µmoles) with 4 GBq 177Lu at Various SA of 177Lu (#95)
8:30 AM
Wouter AP Breeman
Conference Breakfast: Moderated Poster Walk - Prostate tumours
Dose-finding studies of 177Lu-DOTA-peptides for PRRT. Studies on formulation by varying Specific Activity (SA) of 177Lu-DOTA-peptides as a tool to optimize activity at contant amount of peptide (#103)
8:30 AM
Wouter AP Breeman
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours